Journal: Bioanalysis
Article Title: Analytical considerations for reducing the matrix effect for the sphingolipidome quantification in whole blood
doi: 10.4155/bio-2021-0098
Figure Lengend Snippet: (A) Correlation between peak intensity and blood volume, shows big matrix effects for high volumes of blood. (B) Comparison of the raw peak intensity or normalized intensity (internal standard 12:0 ceramide or 25:0 ceramide) of Cer(d18:1/20:0), and their linearities against blood volume. (C) Comparison of the raw peak intensity or normalized intensity (internal standard 12:0 Hex1Cer or C15 Hex1Cer-D7) of Hex1Cer(d18:1/20:0), and their linearities against blood volume. (D) Comparison of the raw peak intensity or normalized intensity (internal standard 12:0 SM or 18:1 d9 SM) of SM(d34:1), and the linearity against blood volume. Cer: Ceramide; Hex: Hexosyl; SM: Sphingomyelin.
Article Snippet: C18:0 GM3-d5 (Catalog No. 860073), C15 glucosyl(β) ceramide-d7 (d18:1-d7/15:0; Catalog No. 330729), ceramides (Cer)/sphingosine (Sph) Mixture I (Catalog No. LM6002) containing sphingosine (C17 base), sphinganine (C17 base), sphingosine-1-P (C17 base), sphinganine-1-P (C17 base), lactosyl (β) C12 ceramide (hexosyl [Hex] 2Cer d18:1/12:0), 12:0 sphingomyelin (12:0 sphingomyelins [SM]), glucosyl (β) C12 ceramide (Hex1Cer d18:1/12:0), 12:0 ceramide (d18:1/12:0), 12:0 ceramide-1-P (ceramide-1-phosphate [Cer] P d18:1/12:0), and 25:0 Ceramide (d18:1/25:0), and SPLASH ® LIPIDOMIX ® Mass Spec Standard (Catalog No. 330707) consisting of 15:0–18:1(d7) PC, 15:0–18:1(d7) PE, 15:0–18:1(d7) PS, 15:0–18:1(d7) PG, 15:0–18:1(d7) PI, 15:0–18:1(d7) PA, 18:1(d7) LPC, 18:1(d7) LPE, 18:1(d7) Chol Ester, 18:1(d7) MG,15:0–18:1(d7) DG, 15:0–18:1(d7)-15:0 TG, 18:1(d9) SM and cholesterol (d7) were from Avanti Polar Lipids (AL, USA).
Techniques: